Aragen Life Sciences has appointed Aniel Khubchandani as Chief Executive Officer – Development and Manufacturing Solutions, marking a significant move toward strengthening its global footprint and advancing innovation-led manufacturing capabilities. With a distinguished career spanning over 30 years in life sciences, fine chemicals, and the CDMO (Contract Development and Manufacturing Organization) industry, Aniel brings strategic leadership and a proven track record in operational excellence.
Prior to joining Aragen, Aniel served as Managing Director and CEO at Sekhmet Pharmaventures, where he successfully led the organization through a transformation phase, emphasizing growth, sustainability, and building a high-trust culture. His expertise in API (Active Pharmaceutical Ingredient) solutions and a deep commitment to customer-centric operations have earned him widespread recognition across the pharmaceutical manufacturing ecosystem.
Throughout his career, Aniel has held senior leadership roles at Jubilant Ingrevia Limited and Jubilant Pharmova Limited, where he was responsible for managing global business portfolios, driving growth in specialty ingredients, and spearheading innovation strategies. His leadership consistently focused on maintaining high standards in quality, regulatory compliance, and client satisfaction, enabling sustained success in both domestic and international markets.
At Aragen, Aniel will lead the development and manufacturing vertical, furthering the company’s mission to deliver agile and reliable solutions to life sciences clients worldwide. His appointment aligns with Aragen’s vision to expand globally while fostering innovation and operational agility across its offerings.
“At Aragen, Aniel will help advance the company’s mission of delivering agile, trusted solutions for global life sciences clients.” His extensive experience and strategic mindset are expected to play a key role in accelerating Aragen’s growth trajectory and solidifying its reputation as a trusted global partner in the CDMO sector.
An IICA-certified Independent Director, Aniel has also contributed his insights as a board member for various organizations, further demonstrating his broad industry knowledge and governance expertise. His appointment signifies a major step in Aragen’s journey to scale its capabilities and deliver impactful solutions across the global pharmaceutical and biotechnology value chain.
